title: Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients.
abstract: Gliomas are the most common primary intracranial malignant tumors in adults. Surgical resection followed by optional radiotherapy and chemotherapy is the current standard therapy for glioma patients. Vimentin, a protein of intermediate filament family, could maintain the cellular integrity and participate in several cell signal pathways to modulate the motility and invasion of cancer cells. The purpose of the present research was to identify the relationship between vimentin expression and clinical characteristics and detect the prognostic and predictive ability of vimentin in patients with glioma. To determine the expression of vimentin in glioma tissues, paraffin-embedded blocks from glioma patients by surgical resection were obtained and evaluated by immunohistochemistry. To further investigate the association of vimentin expression with survival, we employed mRNA expression of vimentin genes from the Chinese Glioma Genome Atlas (CGGA) and the GSE 16011 dataset. Kaplan-Meier analysis and Cox regression model were used to statistical analysis. We detected positive vimentin straining in 84 % of high-grade compared to 47 % in low-grade glioma patients. Additionally, vimentin mRNA expression was correlated with glioma grade in both CGGA and GSE16011 dataset. Patients with low vimentin expression have longer survival than high expression. In multivariate analysis, vimentin was an independent significant prognostic factor for high-grade glioma patients. We also identified that glioblastoma patients with low vimentin expression had a better response to temozolomide therapy. Vimentin expression has a significant association with tumor grade and overall survival of high-grade glioma patients. Low vimentin expression may benefit from temozolomide therapy.
authors.affiliation: Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, No. 246 XueFu Road, NanGang District, Harbin, Heilongjiang Province, 150086, China.|Chinese Glioma Cooperative Group (CGCG), Beijing, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Lin
authors.affiliation: Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, No. 246 XueFu Road, NanGang District, Harbin, Heilongjiang Province, 150086, China.|Chinese Glioma Cooperative Group (CGCG), Beijing, China.
authors.forename: Guangzhi
authors.initials: G
authors.lastname: Wang
authors.affiliation: Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, No. 246 XueFu Road, NanGang District, Harbin, Heilongjiang Province, 150086, China.|Chinese Glioma Cooperative Group (CGCG), Beijing, China.
authors.forename: Jianguang
authors.initials: J
authors.lastname: Ming
authors.affiliation: Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, No. 246 XueFu Road, NanGang District, Harbin, Heilongjiang Province, 150086, China.|Chinese Glioma Cooperative Group (CGCG), Beijing, China.
authors.forename: Xiangqi
authors.initials: X
authors.lastname: Meng
authors.affiliation: Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, No. 246 XueFu Road, NanGang District, Harbin, Heilongjiang Province, 150086, China.|Chinese Glioma Cooperative Group (CGCG), Beijing, China.
authors.forename: Bo
authors.initials: B
authors.lastname: Han
authors.affiliation: Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, No. 246 XueFu Road, NanGang District, Harbin, Heilongjiang Province, 150086, China.|Chinese Glioma Cooperative Group (CGCG), Beijing, China.
authors.forename: Bo
authors.initials: B
authors.lastname: Sun
authors.affiliation: Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, No. 246 XueFu Road, NanGang District, Harbin, Heilongjiang Province, 150086, China. caijinquan666777@126.com.|Chinese Glioma Cooperative Group (CGCG), Beijing, China. caijinquan666777@126.com.
authors.forename: Jinquan
authors.initials: J
authors.lastname: Cai
authors.affiliation: Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, No. 246 XueFu Road, NanGang District, Harbin, Heilongjiang Province, 150086, China. jcl6688@163.com.|Chinese Glioma Cooperative Group (CGCG), Beijing, China. jcl6688@163.com.
authors.forename: Chuanlu
authors.initials: C
authors.lastname: Jiang
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D005910:Glioma / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology*; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate; D000077204:Temozolomide; D014746:Vimentin / Q000235:genetics / Q000378:metabolism*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D014408:Biomarkers, Tumor; D012333:RNA, Messenger; D014746:Vimentin; D003606:Dacarbazine; D000077204:Temozolomide
keywords: Glioma; Survival; Temozolomide; Vimentin